Junshi Biosciences' Loqtorzi has received MHRA approval for NPC and ESCC, marking the first NPC drug and a PD-L1-independent ...

Keymed Biosciences has licensed global rights for CM336, excluding Greater China, to Platina Medicines in a deal worth up to ...

Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) ...

US clinical-stage biopharmaceutical company Boston Pharmaceuticals has announced positive results from a Phase II study ...

Amferia's peptide-based hydrogel boosts antibiotic effectiveness by up to 64 times against resistant bacteria, stabilizing ...

Belgian biotech start-up ExeVir Bio says it has appointed Michael Garrett as its new chief executive (CEO), effective 1 Dec.

Anthos Therapeutics has presented data at the American Heart Association (AHA) Scientific Sessions from its landmark ...

In yet another sign of the mounting interest in radiopharmaceuticals, Tongrui Biopharma, a Chinese innovator in this area, ...

Last week saw US pharma major AbbVie release disappointing Phase II trial results on its emraclidine in schizophrenia, which ...

US antiviral giant Gilead Sciences on Friday unveiled two-and-a-half-year interim analysis from the ongoing Phase III ASSURE ...

Johnson & Johnson has filed a lawsuit seeking validation of its rebate model for 340B drugs, which offers post-sale rebates instead of upfront discounts. The initiative, criticized by hospitals and ...

Zai Lab has priced its public offering at $25.50 per share, targeting $200 million for corporate purposes. The fundraising ...